{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T18:27:46Z","timestamp":1786991266971,"version":"build-2736575974"},"reference-count":18,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,12,27]],"date-time":"2024-12-27T00:00:00Z","timestamp":1735257600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["jaci-global.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Allergy and Clinical Immunology: Global"],"published-print":{"date-parts":[[2025,5]]},"DOI":"10.1016\/j.jacig.2024.100399","type":"journal-article","created":{"date-parts":[[2024,12,28]],"date-time":"2024-12-28T11:41:38Z","timestamp":1735386098000},"page":"100399","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Acute\/baseline ratios of all 3 MC mediator metabolites can enhance diagnosis and management of mast cell activation syndrome"],"prefix":"10.1016","volume":"4","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6830-2190","authenticated-orcid":false,"given":"Joseph H.","family":"Butterfield","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adela","family":"Taylor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jacig.2024.100399_bib1","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1097\/ACI.0000000000000768","article-title":"Mast cell activation syndrome: is anaphylaxis part of the phenotype? A\u00a0systemic review","volume":"21","author":"Sabato","year":"2021","journal-title":"Curr Opin Allergy Clin Immunol"},{"key":"10.1016\/j.jacig.2024.100399_bib2","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1016\/j.jaip.2018.11.045","article-title":"Doctor, I think I am suffering from MCAS: differential diagnosis and separating facts from fiction","volume":"7","author":"Valent","year":"2019","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jacig.2024.100399_bib3","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1159\/000501079","article-title":"Why the 20%\u00a0+ 2 tryptase formula is a diagnostic gold standard for severe systemic mast cell activation and mast cell activation syndrome","volume":"180","author":"Valent","year":"2019","journal-title":"Int Arch Allergy Immunol"},{"key":"10.1016\/j.jacig.2024.100399_bib4","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1016\/j.jaip.2014.06.011","article-title":"Mast cell activation syndrome: improved identification by combined determinations of serum tryptase and 24-hour urine 11\u03b2-prostaglandin2\u03b1","volume":"2","author":"Ravi","year":"2014","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jacig.2024.100399_bib5","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1159\/000144042","article-title":"Prevention of mast cell activation disorder-associated clinical sequelae of excessive prostaglandin D2 production","volume":"147","author":"Butterfield","year":"2008","journal-title":"Int Arch Allergy Immunol"},{"key":"10.1016\/j.jacig.2024.100399_bib6","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1080\/1744666X.2019.1596800","article-title":"Recent advances in our understanding of mast cell activation\u2014or should it be mast cell mediator disorders?","volume":"15","author":"Theoharides","year":"2019","journal-title":"Expert Rev Clin Immunol"},{"key":"10.1016\/j.jacig.2024.100399_bib7","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1016\/j.jaci.2018.09.014","article-title":"Effect of IL-33 on de novo synthesized mediators from human mast cells","volume":"143","author":"Theoharides","year":"2019","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jacig.2024.100399_bib8","doi-asserted-by":"crossref","first-page":"2533","DOI":"10.1016\/j.jaip.2020.02.021","article-title":"The utility of measuring urinary metabolites of mast cell mediators in systemic mastocytosis and mast cell activation syndrome","volume":"8","author":"Butterfield","year":"2020","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jacig.2024.100399_bib9","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1016\/j.iac.2018.04.011","article-title":"Mast cell mediators of significance in clinical practice in mastocytosis","volume":"38","author":"Butterfield","year":"2018","journal-title":"Immunol Allergy Clin North Am"},{"key":"10.1016\/j.jacig.2024.100399_bib10","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.1016\/j.jaci.2021.08.007","article-title":"Defining baseline variability of serum tryptase levels improves accuracy in identifying anaphylaxis","volume":"149","author":"Mateja","year":"2022","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jacig.2024.100399_bib11","doi-asserted-by":"crossref","first-page":"7626","DOI":"10.1073\/pnas.80.24.7626","article-title":"Generation and metabolism of 5-lipoxygenase pathway leukotrienes by human eosinophils: predominant production of leukotriene C4","volume":"80","author":"Weller","year":"1983","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.jacig.2024.100399_bib12","doi-asserted-by":"crossref","first-page":"3855","DOI":"10.4049\/jimmunol.147.11.3855","article-title":"IL-3 and IL-5 prime normal human eosinophils to produce leukotriene C3 in response to soluble agonists","volume":"147","author":"Takafuji","year":"1991","journal-title":"J Immunol"},{"key":"10.1016\/j.jacig.2024.100399_bib13","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1183\/09031936.00093407","article-title":"Increased urinary leukotriene E4 concentration in patients with eosinophilic pneumonia","volume":"32","author":"Ono","year":"2008","journal-title":"Eur Respir J"},{"key":"10.1016\/j.jacig.2024.100399_bib14","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1111\/j.1365-2222.2008.03104.x","article-title":"Increased production of cysteinyl leukotrienes and prostaglandin D2 during human anaphylaxis","volume":"39","author":"Ono","year":"2008","journal-title":"Clin Exp Allergy"},{"key":"10.1016\/j.jacig.2024.100399_bib15","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1016\/j.jaci.2016.04.042","article-title":"Eosinophil production of prostaglandin D2 in patients with aspirin-exacerbated respiratory disease","volume":"138","author":"Feng","year":"2016","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jacig.2024.100399_bib16","doi-asserted-by":"crossref","first-page":"1830","DOI":"10.1172\/JCI110938","article-title":"Effects of dexamethasone on mediator release from human lung fragments and purified human lung mast cells","volume":"71","author":"Schleimer","year":"1983","journal-title":"J Clin Invest"},{"key":"10.1016\/j.jacig.2024.100399_bib17","doi-asserted-by":"crossref","first-page":"2542","DOI":"10.1016\/j.jaip.2023.02.017","article-title":"Increased excretion of mast cell mediator metabolites during mast cell activation syndrome","volume":"11","author":"Butterfield","year":"2023","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jacig.2024.100399_bib18","doi-asserted-by":"crossref","first-page":"1594","DOI":"10.1016\/j.jaip.2024.02.042","article-title":"A US-based multicenter retrospective report of perioperative anaphylaxis, 2010-2021","volume":"12","author":"Gonzalez-Estrada","year":"2024","journal-title":"J Allergy Clin Immunol Pract"}],"container-title":["Journal of Allergy and Clinical Immunology: Global"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2772829324001954?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2772829324001954?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,5,10]],"date-time":"2025-05-10T15:42:29Z","timestamp":1746891749000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2772829324001954"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5]]},"references-count":18,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,5]]}},"alternative-id":["S2772829324001954"],"URL":"https:\/\/doi.org\/10.1016\/j.jacig.2024.100399","relation":{},"ISSN":["2772-8293"],"issn-type":[{"value":"2772-8293","type":"print"}],"subject":[],"published":{"date-parts":[[2025,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Acute\/baseline ratios of all 3 MC mediator metabolites can enhance diagnosis and management of mast cell activation syndrome","name":"articletitle","label":"Article Title"},{"value":"Journal of Allergy and Clinical Immunology: Global","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jacig.2024.100399","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Inc. on behalf of the American Academy of Allergy, Asthma & Immunology.","name":"copyright","label":"Copyright"}],"article-number":"100399"}}